Literature DB >> 22357440

Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.

Yasemin Sanli1, Cuneyt Turkmen, Baris Bakir, Cem Iyibozkurt, Sevda Ozel, Duygu Has, Ebru Yilmaz, Samet Topuz, Ekrem Yavuz, Seher Nilgun Unal, Ayse Mudun.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the diagnostic value of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT in comparison with MRI for the detection of recurrent ovarian cancer.
METHODS: Forty-seven patients with suspected ovarian cancer recurrence after total ablative or cytoreductive surgery, as well as neoadjuvant or adjuvant chemotherapy, who had undergone (18)F-FDG PET/CT imaging were recruited for the present study. All patients also underwent MRI within a month of (18)F-FDG PET/CT for the same purpose. Recurrent cancer in the abdomen and pelvis was evaluated in each of the 47 patients and classified as either distant metastasis or local pelvic recurrence involving the vaginal stump, peritoneal implants, supradiaphragmatic region, and/or abdominal and pelvic lymph nodes. Special attention was paid to peritoneal implants. These were divided into five groups according to size of the implants: less than 0.5 cm (group 1), 0.5-1 cm (group 2), 1-2 cm (group 3), 2-3 cm (group 4), and larger than 3 cm (group 5). PET/CT findings were compared with abdominopelvic MR findings. Statistical analysis was carried out using the Wilcoxon signed rank test.
RESULTS: Thirty-nine of 47 patients were found to have recurrent ovarian cancer. Both PET/CT and MRI were negative for recurrence in six patients. Overall sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of PET/CT were 97.5, 100, 100, 87.5, and 97.8%, respectively, whereas those of MRI were 95, 85.7, 97.4, 75, and 93.6%, respectively. For the peritoneal implants in groups 2 and 3, the sensitivity, negative predictive value, and diagnostic accuracy values of PET/CT were significantly better than those of MRI (P<0.05).
CONCLUSION: The present study revealed that PET/CT is similar to conventional MRI for the detection of recurrent ovarian cancer. PET/CT has greater accuracy in the detection of small-to-medium-sized (<2 cm) peritoneal implants compared with MRI. This may affect surgical decision making.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357440     DOI: 10.1097/MNM.0b013e32834fc5bf

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

1.  The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Authors:  Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

Review 2.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 3.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

Review 4.  Diagnostic accuracy of 18F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Sang-Woo Lee
Journal:  Br J Radiol       Date:  2017-11-21       Impact factor: 3.039

5.  Oral gastrografin radiography for the evaluation of the functional impact of peritoneal carcinomatosis: Correlation with clinicopathological findings.

Authors:  Lie-Jun Mei; Lin-Wei Wang; Chao-Qun Huang; Xiao-Jun Yang; Yan Li
Journal:  Mol Clin Oncol       Date:  2015-06-09

6.  Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Authors:  P Peng; Z H Zhu; Z J Zhong; K Zheng; J X Yang; D Y Cao; K Shen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

Review 7.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

8.  Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent.

Authors:  M K Ravoori; S Singh; R Bhavane; A K Sood; B Anvari; J Bankson; A Annapragada; V Kundra
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

9.  Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.

Authors:  Daniela Rusu; Thomas Carlier; Mathilde Colombié; Dorothée Goulon; Vincent Fleury; Nicolas Rousseau; Dominique Berton-Rigaud; Isabelle Jaffre; Françoise Kraeber-Bodéré; Loic Campion; Caroline Rousseau
Journal:  Front Med (Lausanne)       Date:  2015-07-22

10.  The effectiveness of dual-phase 18F-FDG PET/CT in the detection of epithelial ovarian carcinoma: a pilot study.

Authors:  Jae Kwan Lee; Kyung-Jin Min; Kyeong A So; Sungeun Kim; Jin Hwa Hong
Journal:  J Ovarian Res       Date:  2014-02-05       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.